ovarian neoplasms/tyrosine

BACKGROUND OF THE INVENTION Throughout this application, various publications are referenced by Arabic numerals in brackets. Full citations for these publications may be found listed at the end of the specification immediately preceding the claims. The disclosures of these publications in their

The present invention relates to a method for treating solid cancers including non-small cell lung cancer, pancreatic, bladder, breast and ovarian cancer, prostate cancer, as well as advanced biliary tract cancers comprising administering at least one antineoplastic agent such as a nucleotide

The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 11, 2016, is named OTJ_009US_Sequence.txt and is 27,712 bytes in

CROSS-REFERENCE TO RELATED APPLICATIONS Not applicable. BACKGROUND OP THE INVENTION 1. Field of the Invention The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel arylamide and hetereoarylamide compounds that

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 23, 2013, is named PRD2659USDIV3_SL.txt and is 825 bytes in size. BACKGROUND OF THE

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal

BACKGROUND OF THE INVENTION The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase. Protein kinases are enzymes that serve as key components of signal